Trial Profile

A Randomized, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Mar 2025 According to a Zealand Pharma media release, detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial published at the Obesity Society Annual Meeting (ObesityWeek) 2024.
20 Jun 2024 According to a Zealand Pharma media release, the final results will be based on all collected data including complete post-treatment follow-up from the third cohort. Zealand expects to present more details on the 16-week results from Part 2 of the MAD trial at a scientific conference later this year. The company to host a conference call to discuss topline results June 20, at 8:00 PM CET / 2:00 PM ET.
20 Jun 2024 Results presented in the Zealand Pharma Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com